Quantitative measurement of PTEN loss improves risk assessment in prostate cancer (2019)
- Authors:
- USP affiliated authors: REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1097/01.JU.0000555707.15264.f6
- Subjects: NEOPLASIAS; PRÓSTATA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2019
- Source:
- Título do periódico: The Journal of Urology
- ISSN: 0022-5347
- Volume/Número/Paginação/Ano: v. 201, suppl. 4, p. e403, res. MP28-02, 2019
- Conference titles: Annual Meeting American Urological Association -AUA
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
JAMASPISHVILI, Tamara et al. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer. The Journal of Urology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/01.JU.0000555707.15264.f6. Acesso em: 16 abr. 2024. , 2019 -
APA
Jamaspishvili, T., Patel, P., Yi Niu, D., Vidotto, T., Caven, I., Livergant, R., et al. (2019). Quantitative measurement of PTEN loss improves risk assessment in prostate cancer. The Journal of Urology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1097/01.JU.0000555707.15264.f6 -
NLM
Jamaspishvili T, Patel P, Yi Niu D, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson A-M, Lotan T, Squire JA, Peng Y, Berman D, Reis RB dos. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer [Internet]. The Journal of Urology. 2019 ; 201 e403.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1097/01.JU.0000555707.15264.f6 -
Vancouver
Jamaspishvili T, Patel P, Yi Niu D, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson A-M, Lotan T, Squire JA, Peng Y, Berman D, Reis RB dos. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer [Internet]. The Journal of Urology. 2019 ; 201 e403.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1097/01.JU.0000555707.15264.f6 - Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
- Emerging role of PTEN loss in evasion of the immune response to tumours
- TCGA analysis identifies distinct genomic features of oncogenic progression and outcome associated with hemizygous PTEN loss tumors
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
- Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Analysis of the impact of ZEB1 expression on pathway enrichment and immune cell abundance in prostate cancer
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Application of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting PTEN loss in diagnostic prostate cancer needle biopsies
Informações sobre o DOI: 10.1097/01.JU.0000555707.15264.f6 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
